Neuromolecular Etiology of Bipolar Disorder: Possible Therapeutic Targets of Mood Stabilizers

키워드

참고문헌 (106)

1. Goodwin FK, "Manic-depressive illness", pp.402~502 (1990), Oxford University Press
2. Potter WZ, "Catecholamines in depression : an update", Clin Chem, 40, pp.279~287 (1994)
3. Nutt DJ, "Altered central alpha 2-adrenoceptor sensitivity in panic disorder", Arch Gen Psychiatry, 46, pp.165~169 (1989)
4. Swann AC, "Depressive mania versus agitated depression : biogenic amine and hypothalamic-pituitary-adrenocortical function", Biol Psychiatry, 35, pp.803~813 (1994)
5. Lenox RH, "Overview of the mechanism of action of lithium in the brain: fifty-year update", J Clin Psychiatry, 61(Suppl 9), pp.5~15 (2000)
6. Rowe MK, "Lithium neuroprotection : molecular mechanisms and clinical implications", Expert Rev Mol Med, 6, pp.1~18 (2004)
7. Quiroz JA, "Novel insights into lithium’s mechanism of action : neurotrophic and neuroprotective effects", Neuropsychobiology, 62, pp.50~60 (2010)
8. Chen G, "Attenuation of cyclic AMP production by carbamazepine", J Neurochem, 67, pp.2079~2086 (1996)
9. Ather Muneer, "Kynurenine Pathway of Tryptophan Metabolism in Neuropsychiatric Disorders: Pathophysiologic and Therapeutic Considerations", Clinical Psychopharmacology and Neuroscience, 18(4), pp.507~526 (2020), 대한정신약물학회[DOI]
10. Pourhamzeh M, "The roles of serotonin in neuropsychiatric disorders", Cell Mol Neurobiol (2021)[DOI]
11. Goodwin FK, "Suicide, aggression, and depression. A theoretical framework for future research", Ann N Y Acad Sci, 487, pp.351~355 (1986)
12. Meltzer HY, "Serotonin uptake in blood platelets of psychiatric patients", Arch Gen Psychiatry, 38, pp.1322~1326 (1981)
13. Asberg M, "Cerebrospinal fluid studies in suicide. An overview", Ann N Y Acad Sci, 487, pp.243~255 (1986)
14. Hughes JH, "Effects of acute tryptophan depletion on mood and suicidal ideation in bipolar patients symptomatically stable on lithium", Br J Psychiatry, 177, pp.447~451 (2000)
15. Berk M, "Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder", Acta Psychiatr Scand Suppl, (434), pp.41~49 (2007)
16. Yadid G, "Dynamics of the dopaminergic system as a key component to the understanding of depression", Prog Brain Res, 172, pp.265~286 (2008)
17. Manji HK, "Bipolar disorder: biological models and their clinical application", pp.1~40 (1997), Marcel Dekker
18. Shah PJ, "Clinical and psychometric correlates of dopamine D2 binding in depression", Psychol Med, 27, pp.1247~1256 (1997)
19. Lykouras L, "Association of biogenic amine metabolites with symptomatology in delusional(psychotic)and nondelusional depressed patients", Prog Neuropsychopharmacol Biol Psychiatry, 19, pp.877~887 (1995)
20. Murphy DL, "Regular induction of hypomania by L-dopa in"bipolar"manic-depressive patients", Nature, 229, pp.135~136 (1971)
21. Jacobs D, "Dextroamphetamine-induced arousal in human subjects as a model for mania", Psychol Med, 16, pp.323~329 (1986)
22. Anand A, "Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder", Biol Psychiatry, 45, pp.972~978 (1999)
23. Cousins DA, "The role of dopamine in bipolar disorder", Bipolar Disord, 11, pp.787~806 (2009)
24. Berggren U, "Effects of acute lithium administration on conditioned avoidance behavior and monoamine synthesis in rats", J Neural Transm, 47, pp.1~10 (1980)
25. Bunney WE Jr, "Possible receptor effects of chronic lithium administration", Neuropharmacology, 22(3 Spec No), pp.367~372 (1983)
26. Massat I, "Bipolar disorders: basic mechanisms and therapeutic implications", pp.143~165 (2000), Marcel Dekker
27. Shiah IS, "GABA function in mood disorders : an update and critical review", Life Sci, 63, pp.1289~1303 (1998)
28. Prosser J, "Plasma GABA in children and adolescents with mood, behavior, and comorbid mood and behavior disorders : a preliminary study", J Child Adolesc Psychopharmacol, 7, pp.181~199 (1997)
29. Brambilla P, "GABAergic dysfunction in mood disorders", Mol Psychiatry, 8, pp.721~737 (2003)
30. Petty F, "Plasma GABA predicts acute response to divalproex in mania", Biol Psychiatry, 39, pp.278~284 (1996)
31. Post RM, "Mechanisms of action of anticonvulsants in affective disorders : comparisons with lithium", J Clin Psychopharmacol, 12(1 Suppl), pp.23~ (1992)[DOI]
32. Motohashi N, "GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate", Prog Neuropsychopharmacol Biol Psychiatry, 16, pp.571~579 (1992)
33. Vieta E, "Enhanced corticotropin response to corticotropin-releasing hormone as a predictor of mania in euthymic bipolar patients", Psychol Med, 29, pp.971~978 (1999)
34. Rybakowski JK, "The dexamethasone", corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness, 1999, pp.33, 363~370
35. Gallagher P, "Persistent effects of mifepristone(RU-486)on cortisol levels in bipolar disorder and schizophrenia", J Psychiatr Res, 42, pp.1037~1041 (2008)
36. Halbreich U, "Role of estrogen in the aetiology and treatment of mood disorders", CNS Drugs, 15, pp.797~817 (2001)
37. Payne JL, "The role of estrogen in mood disorders in women", Int Rev Psychiatry, 15, pp.280~290 (2003)
38. Bauer M, "Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging", Pharmacopsychiatry, 36(Suppl 3), pp.S215~S221 (2003)
39. Carlson PJ, "Neural circuitry and neuroplasticity in mood disorders : insights for novel therapeutic targets", NeuroRx, 3, pp.22~41 (2006)
40. Manji HK, "The underlying neurobiology of bipolar disorder", World Psychiatry, 2, pp.136~146 (2003)
41. Cuellar AK, "Distinctions between bipolar and unipolar depression", Clin Psychol Rev, 25, pp.307~339 (2005)
42. Looney SW, "Meta-analysis of erythrocyte Na, K-ATPase activity in bipolar illness", Depress Anxiety, 5, pp.53~65 (1997)
43. El-Mallakh RS, "Intracerebroventricular administration of ouabain as a model of mania in rats", Bipolar Disord, 5, pp.362~365 (2003)
44. Kim SH, "Dose-dependent effect of intracerebroventricular injection of ouabain on the phosphorylation of the MEK1", 2-ERK1, Prog Neuropsychopharmacol Biol Psychiatry, pp.2008, 32[DOI]
45. Soares JC, "Bipolar disorders:basic mechanisms and therapeutic implications", pp.167~177 (2000), Marcel Dekker
46. Pettegrew JW, "Membrane biophysical studies of lymphocytes and erythrocytes in manic-depressive illness", J Affect Disord, 4, pp.237~247 (1982)
47. Hitzemann RJ, "On the physical properties of red cell ghost membranes in the affective disorders and psychoses. A fluorescence polarization study", J Affect Disord, 10, pp.227~232 (1986)
48. Shelton RC, "Intracellular mechanisms of antidepressant drug action", Harv Rev Psychiatry, 8, pp.161~174 (2000)
49. Manji HK, "Guanine nucleotide-binding proteins in bipolar affective disorder. Effects of long-term lithium treatment", Arch Gen Psychiatry, 52, pp.135~144 (1995)
50. Young LT, "Stimulatory G-protein alpha-subunit mRNA levels are not increased in autopsied cerebral cortex from patients with bipolar disorder", Brain Res Mol Brain Res, 42, pp.45~50 (1996)
51. Schreiber G, "Hyperfunctional G proteins in mononuclear leukocytes of patients with mania", Biol Psychiatry, 29, pp.273~280 (1991)
52. Avissar S, "Differential G protein measures in mononuclear leukocytes of patients with bipolar mood disorder are state dependent", J Affect Disord, 43, pp.85~93 (1997)
53. Young LT, "Cerebral cortex Gs alpha protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder", J Neurochem, 61, pp.890~898 (1993)
54. Mann JJ, "Reduced sensitivity of lymphocyte beta-adrenergic receptors in patients with endogenous depression and psychomotor agitation", N Engl J Med, 313, pp.715~720 (1985)
55. cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder, "J Neurochem", 1997, 297~304
56. Fields A, "Increased cyclic AMP-dependent protein kinase activity in postmortem brain from patients with bipolar affective disorder", J Neurochem, 73, pp.1704~1710 (1999)
57. Chang A, "cAMP-Dependent protein kinase(PKA)subunit mRNA levels in postmortem brain from patients with bipolar affective disorder(BD)", Brain Res Mol Brain Res, 116, pp.27~37 (2003)
58. Perez J, "Abnormalities of cAMP-dependent endogenous phosphorylation in platelets from patients with bipolar disorder", Am J Psychiatry, 152, pp.1204~1206 (1995)
59. Nestler EJ, "Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex", J Neurochem, 53, pp.1644~1647 (1989)
60. Newman M, "Lithium at therapeutic concentrations inhibits human brain noradrenaline-sensitive cyclic AMP accumulation", Brain Res, 278, pp.380~381 (1983)
61. Mathews R, "Increased G alpha q", 11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder, 1997, pp.41, 649~656
62. Friedman E, "Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects", J Neurochem, 67, pp.1145~1152 (1996)
63. Brown AS, "Elevated platelet membrane phosphatidylinositol-4, 5-bisphosphate in bipolar mania", Am J Psychiatry, 150, pp.1252~1254 (1993)
64. Soares JC, "Bipolar disorders: basic mechanisms and therapeutic implications", pp.179~200 (2000), Marcel Dekker
65. Shimon H, "Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder", Am J Psychiatry, 154, pp.1148~1150 (1997)
66. Friedman E, "Altered platelet protein kinase C activity in bipolar affective disorder, manic episode", Biol Psychiatry, 33, pp.520~525 (1993)
67. Wang HY, "Enhanced protein kinase C activity and translocation in bipolar affective disorder brains", Biol Psychiatry, 40, pp.568~575 (1996)
68. Hahn CG, "Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder", Bipolar Disord, 1, pp.81~86 (1999)
69. Nahorski SR, "Lithium and the phosphoinositide cycle : an example of uncompetitive inhibition and its pharmacological consequences", Trends Pharmacol Sci, 12, pp.297~303 (1991)
70. Ikonomov OC, "Molecular mechanisms underlying mood stabilization in manic-depressive illness : the phenotype challenge", Am J Psychiatry, 156, pp.1506~1514 (1999)
71. Manji HK, "Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents : therapeutic implications", J Clin Psychiatry, 60(Suppl 2), pp.27~39 (1999)
72. Soares JC, "Concurrent measures of protein kinase C and phosphoinositides in lithium-treated bipolar patients and healthy individuals : a preliminary study", Psychiatry Res, 95, pp.109~118 (2000)
73. Watson DG, "Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells : potentiation by muscarinic receptor activation", J Neurochem, 67, pp.767~777 (1996)
74. Chen G, "Lithium regulates PKCmediated intracellular cross-talk and gene expression in the CNS in vivo", Bipolar Disord, 2(3 Pt 2), pp.217~236 (2000)
75. Einat H, "Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats : implications for the development of novel therapeutics for bipolar disorder", Neuropsychobiology, 55, pp.123~131 (2007)
76. Yildiz A, "Protein kinase C inhibition in the treatment of mania : a double-blind, placebo-controlled trial of tamoxifen", Arch Gen Psychiatry, 65, pp.255~263 (2008)
77. Förstner U, "Decreased agonist-stimulated Ca2＋ response in neutrophils from patients under chronic lithium therapy", Eur Arch Psychiatry Clin Neurosci, 243, pp.240~243 (1994)
78. van Calker D, "Increased sensitivity to agonist stimulation of the Ca2＋ response in neutrophils of manic-depressive patients : effect of lithium therapy", Neuropsychobiology, 27, pp.180~183 (1993)
79. Dubovsky SL, "Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder", Eur Arch Psychiatry Clin Neurosci, 243, pp.229~234 (1994)
80. Muresanu DF, "Neuroprotection and neuroplasticity-a holistic approach and future perspectives", J Neurol Sci, 257, pp.38~43 (2007)
81. Nonaka S, "Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx", Proc Natl Acad Sci U S A, 95, pp.2642~2647 (1998)
82. Thome J, "cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment", J Neurosci, 20, pp.4030~4036 (2000)
83. Chen B, "Lithium and valproate differentially regulate brain regional expression of phosphorylated CREB and c-Fos", Brain Res Mol Brain Res, 70, pp.45~53 (1999)
84. Manji HK, "Neuroplasticity and cellular resilience in mood disorders", Mol Psychiatry, 5, pp.578~593 (2000)
85. Yuan PX, "The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth", J Biol Chem, 276, pp.31674~31683 (2001)
86. Pap M, "Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase", Akt cell survival pathway, 1998, pp.273, 19929~19932
87. Beurel E, "The paradoxical pro-and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways", Prog Neurobiol, 79, pp.173~189 (2006)
88. Hye Ji Min, "Association of the Brain-derived Neurotrophic Factor Gene and Clinical Features of Bipolar Disorder in Korea", Clinical Psychopharmacology and Neuroscience, 10(3), pp.163~167 (2012), 대한정신약물학회
89. Chen G, "Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants", Psychosom Med, 61, pp.599~617 (1999)
90. Eldar-Finkelman H, "Glycogen synthase kinase 3 : an emerging therapeutic target", Trends Mol Med, 8, pp.126~132 (2002)
91. Ather Muneer, "Wnt and GSK3 Signaling Pathways in Bipolar Disorder: Clinical and Therapeutic Implications", Clinical Psychopharmacology and Neuroscience, 15(2), pp.100~114 (2017), 대한정신약물학회[DOI]
92. Kim NR, "Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.633~642 (2008)
93. Drevets WC, "Subgenual prefrontal cortex abnormalities in mood disorders", Nature, 386, pp.824~827 (1997)
94. Drevets WC, "Neuroimaging studies of mood disorders", Biol Psychiatry, 48, pp.813~829 (2000)
95. 정재경, "Circadian Rhythm Characteristics in Mood Disorders: Comparison among Bipolar I Disorder, Bipolar II Disorder and Recurrent Major Depressive Disorder", Clinical Psychopharmacology and Neuroscience, 10(2), pp.110~116 (2012), 대한정신약물학회[DOI]
96. Ahn YM, "Chronotype distribution in bipolar I disorder and schizophrenia in a Korean sample", Bipolar Disord, 10, pp.271~275 (2008)
97. Barbini B, "The unipolar-bipolar dichotomy and the response to sleep deprivation", Psychiatry Res, 79, pp.43~50 (1998)
98. Wehr TA, "Sleep reduction as a final common pathway in the genesis of mania", Am J Psychiatry, 144, pp.201~204 (1987)
99. SCH 23390 binding and dopamine-stimulated adenylate cyclase in the rat limbic system, "Neurosci Lett", 1990, 224~227
100. Abarca C, "Cocaine sensitization and reward are under the influence of circadian genes and rhythm", Proc Natl Acad Sci U S A, 99, pp.9026~9030 (2002)
101. Iwahana E, "Effect of lithium on the circadian rhythms of locomotor activity and glycogen synthase kinase-3 protein expression in the mouse suprachiasmatic nuclei", Eur J Neurosci, 19, pp.2281~2287 (2004)
102. Seo MK, "Early life stress increases stress vulnerability through BDNF gene epigenetic changes in the rat hippocampus", Neuropharmacology, 105, pp.388~397 (2016)
103. Eun-Jeong Joo, "Significant Shortening of Leukocyte Telomere Length in Korean Patients with Bipolar Disorder 1", Clinical Psychopharmacology and Neuroscience, 19(3), pp.559~563 (2021), 대한정신약물학회[DOI]
104. Tsankova N, "Epigenetic regulation in psychiatric disorders", Nat Rev Neurosci, 8, pp.355~367 (2007)
105. Sarkisova KY, "Maternal care exerts diseasemodifying effects on genetic absence epilepsy and comorbid depression", Genes Brain Behav, 17, pp.e12477~ (2018)
106. Szyf M, "Maternal care, the epigenome and phenotypic differences in behavior", Reprod Toxicol, 24, pp.9~19 (2007)

관련 논문AI추천